Inventiva SACA

2,7800

11-марта-25 12:25:14

15 мин. задержка

Акции

-0,1050

-3,64%

Сегодняшний диапазон

2,7800 - 2,7800

ISIN

FR0013233012

Источник

Cboe

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

25 июл 2024 16:00:00 Источник Nasdaq GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

19 июл 2024 11:30:00 Источник Nasdaq GlobeNewswire
Inventiva announces a €20.1 million issuance of royalty certificates

18 июл 2024 02:30:00 Источник Nasdaq GlobeNewswire
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

05 июл 2024 16:00:00 Источник Nasdaq GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

21 июн 2024 16:05:00 Источник Nasdaq GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

21 июн 2024 16:00:00 Источник Nasdaq GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30 май 2024 02:30:00 Источник Nasdaq GlobeNewswire
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

30 май 2024 02:30:00 Источник Nasdaq GlobeNewswire
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

22 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

21 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

16 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

13 май 2024 02:30:00 Источник Nasdaq GlobeNewswire
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03 апр 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces the nomination of Andre Turenne as Director

28 мар 2024 03:00:00 Источник Nasdaq GlobeNewswire
Inventiva reports its 2023 full-year results

27 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 мар 2024 16:00:00 Источник Nasdaq GlobeNewswire
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 фев 2024 16:35:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.